Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Background: Cohort studies have reported that midlife high total serum cholesterol (TC) is associated with increased risk of Alzheimer’s disease (AD) in late-life but findings have been based on few studies and previous reviews have been limited by a lack of compatible data. Objective: We synthesized all high quality data from cohort studies reporting on the association between total serum cholesterol measured and late-life cognitive outcomes including Alzheimer’s disease (AD), vascular dementia (VaD), any dementia, mild cognitive impairment (MCI), and cognitive decline. Methods: The literature was searched up to October 2016 using a registered protocol. Thirty-four articles meeting study criteria were identified. Seventeen studies published from 1996 to 2014, including 23,338 participants were included in meta-analyses. Results: Relative risk of developing AD for adults with high TC in midlife was 2.14 (95% CI 1.33–3.44) compared with normal cholesterol. Individual studies that could not be pooled also reported high TC in midlife increased the risk of MCI and cognitive decline in late-life. High TC in late-life was not associated with MCI, AD, VaD, any dementia, or cognitive decline. Late-life measured HDL cholesterol and triglycerides were not associated with increased risk of VaD, and HDL was not associated with risk of MCI, AD, or any dementia. There were insufficient data to examine other cholesterol sub-fractions, sex differences, or APOE interactions. Conclusions: Significant gaps in the literature regarding TC and late-life dementia remain. Evidence suggests that high midlife TC increases risk of late-life AD, and may correlate with the onset of AD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meta-analytic evidence found inconsistent evidence from HICs that high LDL-C in midlife, but not in later life, might be a risk factor for cognitive decline, all cause dementia and AD.”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [151]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, midlife obesity, 105,111,112 hypertension, 85,[105][106][107] prehypertension (systolic blood pressure from 120 to 139 mm Hg or diastolic pressure from 80 to 89 mm Hg) 85 and high cholesterol 113 are associated with an increased risk of dementia in later life.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Systematic review evidence has shown there is no consistent evidence linking high cholesterol in midlife or late-life to risk of vascular dementia, and no consistent evidence linking high cholesterol in late-life to risk of AD (5).”
From Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research (2018) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Systematic review evidence has shown there is no consistent evidence linking high cholesterol in midlife or late-life to risk of vascular dementia, and no consistent evidence linking high cholesterol in late-life to risk of AD (5).”
From Oversimplification of Dementia Risk Reduction Messaging Is a Threat to Knowledge Translation in Dementia Prevention Research (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“If there was evidence of heterogeneity and four or more studies were available, random effects meta-analysis was used [18, 19].”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Heterogeneity among studies was examined using standard I2 which estimates the proportion of variance due to heterogeneity [16].”
MethodPRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 1×
“MATERIALS AND METHODS Registration of protocol and reporting The review was registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42015026727) [6] and reported in accordance with the PRISMA checklist [7].”
MethodStang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396 · cited 2×
“Additional quality ratings were conducted for all studies meeting criteria using a checklist adapted from previous reviews, and the Newcastle Ottawa scale [8, 9].”
BackgroundMethodBorenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“For clinical diagnosis of MCI, we accepted Petersen [13], Winblad [14], or other widely accepted clinical research criteria.”
MethodCurrent concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781 · cited 1×
“For clinical diagnosis of MCI, we accepted Petersen [13], Winblad [14], or other widely accepted clinical research criteria.”
MethodHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“However, studies publishing on midlife lacked clear information on the age range of the sample at baseline and the distribution of the sample within midlife and late-life [12, 21].”
Background
Research works printed but not linked: 4
- 2005, Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]
- Slooter AJC, 2000, Neurology, 54, 2357
- Liao PJ, 2015, Int J Clin Exp Med, 8, 19200
- McGuinness B, 2016, Cochrane Database Syst Rev, 1, CD003160
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
Malm, C., Jakobsson, J., & Isaksson, A. (2019) · Sports · doi:10.3390/sports7050127 · Cited by 610
“I proved blood lipid profile [93] Lower risk for cardi pul onary disease in elderly [94,95] and Alzheimer’s [96] No effect on blood lipid profiles in children and adolescents [97] Improved peripheral nerve function [98] Better coordination, balance and reaction [98,99], especially in children and elderly [100] Enhance…”
BackgroundInfluential2025 Alzheimer's disease facts and figures
(2025) · Alzheimer's & Dementia · doi:10.1002/alz.70235 · Cited by 474
Schwarzinger, M., Pollock, B. G., Hasan, O. S. M., Dufouil, C., Rehm, J., Baillot, S., Guibert, Q., Planchet, F., & Luchini, S. (2018) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30022-7 · Cited by 356
Schultz, B. G., Patten, D. K., & Berlau, D. J. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0110-3 · Cited by 229
“life, but not late life, is associated with lower risk of dementia [47], and therefore these participants may have”
BackgroundLoera-Valencia, R., Goikolea, J., Parrado-Fernandez, C., Merino-Serrais, P., & Maioli, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.003 · Cited by 214
“However, a recent meta-analysis comparing data on more than 23,000 patients from 17 studies show that the highest risk for developing AD in relationship with hypercholesterolemia happens in midlife and early stages of aging, while there is no significant correlation with hypercholesterolemia in late life [23].”
BackgroundCholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226
Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets
Dai, L., Zou, L., Meng, L., Qiang, G., Yan, M., & Zhang, Z. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02232-6 · Cited by 194
Anstey, K. J., Ee, N., Eramudugolla, R., Jagger, C., & Peters, R. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190181 · Cited by 187
“…(0.57, 0.73) 6.7% 0.81 6 Carotid atherosclerosis Xu 2015 [20] Yes versus no (carotid medina wall thickness) 1.65 (1.03, 2.26) 31.1% ∼ 2 Cholesterol Anstey 2017 [63] High cholesterol (>6.5 mmol/l) versus non-high-midlife ML 2.14 (1.33, 3.44) 12.9% ∼ 3 Meng 2014 [61] High cholesterol (>6.5…”
BackgroundInfluentialSelf-citationPromoting Successful Cognitive Aging: A Ten-Year Update
Krivanek, T. J., Gale, S. A., McFeeley, B. M., Nicastri, C. M., & Daffner, K. R. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-201462 · Cited by 172
“risk of cognitive impairment or dementia [262, 264].”
Iwagami, M., Qizilbash, N., Gregson, J., Douglas, I., Johnson, M., Pearce, N., Evans, S., & Pocock, S. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00150-1 · Cited by 161
Lipnicki, D. M., Makkar, S. R., Crawford, J. D., Thalamuthu, A., Kochan, N. A., Lima-Costa, M. F., Castro-Costa, E., Ferri, C. P., Brayne, C., Stephan, B., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002853 · Cited by 143
“Further, we did not specifically investigate factors at midlife, when some, such as high cholesterol, exert their strongest late-life cognitive effects [72].”
BackgroundSelf-citationThe insulin resistance by triglyceride glucose index and risk for dementia: population-based study
Hong, S., Han, K., & Park, C. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00758-4 · Cited by 130
“14-fold increased risk of AD dementia but not in late life [35].”
BackgroundShared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
Nordestgaard, L. T., Christoffersen, M., & Frikke‐Schmidt, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179777 · Cited by 141
Wingo, T. S., Cutler, D. J., Wingo, A. P., Le, N.-A., Rabinovici, G. D., Miller, B. L., Lah, J. J., & Levey, A. I. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0648 · Cited by 119
Gong, J., Harris, K., Peters, S. A. E., & Woodward, M. (2021) · BMC Medicine · doi:10.1186/s12916-021-01980-z · Cited by 116
“The evidence for lipids as risk factors for dementia has been mixed, with a meta-analysis suggesting that high total cholesterol in midlife is associated with a greater risk of developing AD [35].”
ResultAssociation between metabolic syndrome and risk of incident dementia in UK Biobank
Qureshi, D., Collister, J. A., Allen, N. E., Kuźma, E., & Littlejohns, T. J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13439 · Cited by 131
“60,61 In contrast, we observed an inverse association between elevated triglycerides and dementia, which may be due to reverse causation, as previous evidence indicates that dementia may lead to changes in metabolism and diet, which ultimately results in lower triglyceridelevelsamongthoseaffected.”
Remote Ischemic Conditioning May Improve Outcomes of Patients With Cerebral Small-Vessel Disease
Wang, Y., Meng, R., Song, H., Liu, G., Yang, H., Cui, D., Zheng, L., Feng, W., Liebeskind, D. S., Fisher, M., et al. (2017) · Stroke · doi:10.1161/strokeaha.117.017691 · Cited by 118
“Dyslipidemia and hyperhomocysteinemia, which can alter gene expression and exert excitotoxicity, are independent risk factors for cognitive impairment, stroke, and Alzheimer disease.(38,39) In our study, there were significant reductions in plasma levels of triglyceride, total cholesterol, LDL, and homocysteine after…”
BackgroundA Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association
Lazar, R. M., Howard, V. J., Kernan, W. N., Aparicio, H. J., Levine, D. A., Viera, A. J., Jordan, L. C., Nyenhuis, D. L., Possin, K. L., Sorond, F. A., et al. (2021) · Stroke · doi:10.1161/str.0000000000000367 · Cited by 109
Duong, M. T., Nasrallah, I. M., Wolk, D. A., Chang, C. C. Y., & Chang, T.-Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.647990 · Cited by 105
Dagres, N., Chao, T.-F., Fenelon, G., Aguinaga, L., Benhayon, D., Benjamin, E. J., Bunch, T. J., Chen, L. Y., Chen, S.-A., Darrieux, F., et al. (2018) · EP Europace · doi:10.1093/europace/euy046 · Cited by 94
Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease
Rudajev, V., & Novotny, J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937056 · Cited by 94
“Thus, indirect mechanisms following atherosclerosis or cerebrovascular damage may play a role in cholesterol-related AD pathology (Hooijmans et al., 2007; Anstey et al., 2017).”
BackgroundSvensson, T., Sawada, N., Mimura, M., Nozaki, S., Shikimoto, R., & Tsugane, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0336-y · Cited by 88
Brain, J., Greene, L., Tang, E. Y. H., Louise, J., Salter, A. B., Beach, S., Turnbull, D. A., Siervo, M., Stephan, B. C. M., & Tully, P. J. (2023) · Frontiers in Epidemiology · doi:10.3389/fepid.2023.1095236 · Cited by 103
“No association was found between high levels of TC in late-life and all-cause dementia (44).”
BackgroundResultInfluentialDagres, N., Chao, T., Fenelon, G., Aguinaga, L., Benhayon, D. A., Benjamin, E. J., Bunch, T. J., Chen, L. Y., Chen, S., Darrieux, F., et al. (2018) · Journal of Arrhythmia · doi:10.1002/joa3.12050 · Cited by 90
Wagner, M., Helmer, C., Tzourio, C., Berr, C., Proust-Lima, C., & Samieri, C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2004 · Cited by 86
Plasma Lipids as Biomarkers for Alzheimer's Disease: A Systematic Review
Agarwal, M., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.12008 · Cited by 83
“A total of 49 articles were studied [1-49].”
BackgroundResultInfluentialPlasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab164 · Cited by 91
Wee, J., Sukudom, S., Bhat, S., Marklund, M., Peiris, N. J., Hoyos, C. M., Patel, S., Naismith, S. L., Dwivedi, G., & Misra, A. (2023) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12395 · Cited by 82
“…inclusion of studies with varying cutoff levels is likely to increase sensitivity, in contrast to prior work, which focused on a cutoff of > 6.5 mmol/L. 10 Owing to the nature of population-based studies, a single lipid measure was used as a marker for dyslipidemia in all but one included study.”
InfluentialAn, Y., Zhang, X., Wang, Y., Wang, Y., Liu, W., Wang, T., Qin, Z., & Xiao, R. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0353-1 · Cited by 80
Yang, Z., Wang, H., Edwards, D., Ding, C., Yan, L., Brayne, C., & Mant, J. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100962 · Cited by 82
“Current systematic reviews have explored the links between blood lipids, atherosclerosis or statin use with dementia and cognitive impairment, but they neither included patients with stroke nor conducted analysis specifically for the stroke subgroup (Anstey et al. 2017; Anstey et al. 2008; Wolters et al. 2018; Meng et…”
BackgroundResultSakurai, K., Toshimitsu, T., Okada, E., Anzai, S., Shiraishi, I., Inamura, N., Kobayashi, S., Sashihara, T., & Hisatsune, T. (2022) · Nutrients · doi:10.3390/nu14204300 · Cited by 84
“Meta-analyses have reported that higher total cholesterol levels in middle age increase the risk of cognitive decline in late life [61].”
BackgroundCardiovascular Risk Factors Across the Life Course and Cognitive Decline: A Pooled Cohort Study
Yaffe, K., Vittinghoff, E., Hoang, T., Matthews, K., Golden, S. H., & Zeki Al Hazzouri, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011747 · Cited by 76
“In our pooled cohort study, we did not observe a significant association between cholesterol and cognitive decline, but evidence for cholesterol as a risk factor for cognitive decline is less robust compared to SBP, FG, and BMI.(50) The effects of cholesterolmay have also been reduced due to the likely mixture of non–…”
ResultNicoletti, A. S. Q., Baschi, R., Cicero, C. E., Iacono, S., Re, V. L., Luca, A., Schirò, G., & Monastero, R. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111821 · Cited by 89
Omar, S. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112797 · Cited by 76
“5 mmol/L) may increase the risk of AD but urge cohort studies to publish their data on this topic to increase the knowledge base [95].”
BackgroundHDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
Kjeldsen, E. W., Nordestgaard, L. T., & Frikke‐Schmidt, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094547 · Cited by 80
Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients
Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 79
The shared role of cholesterol in neuronal and peripheral inflammation
Hansen, S. B., & Wang, H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108486 · Cited by 73
Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01360-0 · Cited by 65
Wang, D., Wang, P., Bian, X., Xu, S., Zhou, Q., Zhang, Y., Ding, M., Han, M., Huang, L., Bi, J., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11118 · Cited by 65
Metabolic Syndrome, Cognitive Impairment and the Role of Diet: A Narrative Review
Kouvari, M., D'Cunha, N. M., Travica, N., Sergi, D., Zec, M. M., Marx, W., & Naumovski, N. (2022) · Nutrients · doi:10.3390/nu14020333 · Cited by 88
“, 2017 [25] Low high-density lipoprotein cholesterol Alzheimer’s disease 3 0.”
BackgroundResultInfluentialChanges in Metabolic Syndrome Status and Risk of Dementia
Lee, J. E., Shin, D. W., Han, K., Kim, D., Yoo, J. E., Lee, J., Kim, S., Son, K. Y., Cho, B., & Kim, M. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010122 · Cited by 62
“Results are mixed for dyslipidemia, use of lipid–lowering agents, and the risk of dementia [35,36].”
BackgroundNordestgaard, L. T., Christoffersen, M., Afzal, S., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa269 · Cited by 60
Lipid levels and the risk of dementia: A dose–response meta‐analysis of prospective cohort studies
Zhu, Y., Liu, X., Zhu, R., Zhao, J., & Wang, Q. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51516 · Cited by 68
“44) for adults with high TC in midlife compared with normal cholesterol.(20) However, sensitivity analysis and publication bias test were not performed in this meta-analysis, which potentially decreased the stability of the pooled results.”
BackgroundFerguson, E. L., Zimmerman, S. C., Jiang, C., Choi, M., Swinnerton, K. N., Choudhary, V., Meyers, T. J., Hoffmann, T. J., Gilsanz, P., Oni‐Orisan, A., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207876 · Cited by 64
“Our results are inconsistent with some prior studies showing a signi fi cant harmful e ff ect of elevated LDL-C 6,11,12,19,36,46 or no e ff ect of HDL-C 10,11,19,20 on dementia risk.”
ResultWu, M., Zhai, Y., Liang, X., Chen, W., Lin, R., Ma, L., Huang, Y., Zhao, D., Liang, Y., Zhao, W., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.842814 · Cited by 66
“Scholars screened 17 studies for a meta-analysis and showed that adults with high total cholesterol (TC) in midlife are at higher risk for AD (Anstey et al., 2017).”
MethodThe role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease
Bossaerts, L., Cacace, R., & Broeckhoven, C. V. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00536-w · Cited by 58
“Despite the separation of brain and peripheral cholesterol pools, epidemiological studies identified a link between high serum cholesterol levels and AD risk [40].”
BackgroundKulas, J. A., Weigel, T. K., & Ferris, H. A. (2020) · Drug Development Research · doi:10.1002/ddr.21643 · Cited by 54
Wei, J., Wang, L., Kulshreshtha, A., & Xu, H. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022959 · Cited by 57
Dunk, M. M., Li, J., Liu, S., Casanova, R., Chen, J., Espeland, M. A., Hayden, K. M., Manson, J. E., Rapp, S. R., Shadyab, A. H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13358 · Cited by 57
“11,12 16 Additionally, higher total and LDL cholesterol levels are associated with greater deposition of AD neuropathological hallmarks in the brain.”
BackgroundPeters, R., Xu, Y., Antikainen, R., Beckett, N., Gussekloo, J., Jagger, C., Jukema, J. W., Keinanen-Kiukaanniemi, S., Rydén, L., Skoog, I., et al. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000519452 · Cited by 51
Self-citationStephen, R., Barbera, M., Peters, R., Ee, N., Zheng, L., Lehtisalo, J., Kulmala, J., Håkansson, K., Chowdhary, N., Dua, T., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.763573 · Cited by 62
Self-citationZimetti, F., Adorni, M. P., Marsillach, J., Marchi, C., Trentini, A., Valacchi, G., & Cervellati, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6695796 · Cited by 49
“This is also the case of HDLcholesterol (HDL-C); indeed, several cross-sectional and longitudinal cohort studies have shown that high levels of HDLC were inversely associated with the risk of developing AD, even though the results of a recent meta-analysis did not support this longitudinal association [21].”
ResultWang, T., Huynh, K., Giles, C., Mellett, N. A., Duong, T., Nguyen, A., Lim, W. L. F., Smith, A., Olshansky, G., Cadby, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12538 · Cited by 46
“9–12 Comprehensive Nuclear Magnetic Resonance (NMR) lipoprotein profiling shows that APOE ε 4 leads to minor increases in nearly all lipoprotein subclasses, whereas APOE ε 2 results in stronger changes to the lipoprotein profile.”
Epidemiology and Risk Factors for Dementia
Dintica, C. S., & Yaffe, K. S. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.011 · Cited by 62
(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
Tang, Q., Wang, F., Yang, J., Peng, H., Li, Y., Li, B., & Wang, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00370 · Cited by 48
LDL cholesterol is associated with higher AD neuropathology burden independent of APOE
Wingo, A. P., Vattathil, S. M., Liu, J., Fan, W., Cutler, D. J., Levey, A. I., Schneider, J. A., Bennett, D. A., & Wingo, T. S. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328164 · Cited by 44
Machado‐Fragua, M. D., Fayossé, A., Yerramalla, M. S., van Sloten, T. T., Tabák, Á. G., Mika Kivimaki, B., Sabia, S., & Singh‐Manoux, A. (2022) · Diabetes Care · doi:10.2337/dc22-0206 · Cited by 48
“Although dyslipidemia, particularly in midlife, has been associated with an increased risk of dementia in previous studies (7–9,12,18), the precise blood lipid that is pertinent for dementia remains the subject of debate (26).”
BackgroundEffect of the Lipid Landscape on the Efficacy of Cell-Penetrating Peptides
Zákány, F., Mándity, I. M., Varga, Z., Panyi, G., Nagy, P., & Kovács, T. (2023) · Cells · doi:10.3390/cells12131700 · Cited by 47
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
Chen, P., Cheng, S.-J., Lin, H.-C., Lee, C.-Y., & Chou, C. (2018) · Behavioural Neurology · doi:10.1155/2018/6929732 · Cited by 47
2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 112
Modulating Effect of Diet on Alzheimer’s Disease
Fernández-Sanz, P., Ruiz-Gabarre, D., & García‐Escudero, V. (2019) · Diseases · doi:10.3390/diseases7010012 · Cited by 43
“Future long-term data on the use of statins as a cholesterol-lowering strategy and the impact that this may have on dementia development may shed some light about the importance of cholesterol on AD development [145].”
BackgroundInfluentialMatton, A., Goikolea, J., Björkhem, I., Paternain, L., Kemppainen, N. M., Laatikainen, T. K., Ngandu, T., Rinne, J. O., Soininen, H. S., Cedazo-Mínguez, Á., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00790-y · Cited by 42
Vascular risk burden is a key player in the early progression of Alzheimer’s disease
Ferrari‐Souza, J. P., Brum, W. S., Hauschild, L. A., Ros, L. U. D., Ferreira, P. C. L., Bellaver, B., Leffa, D. T., Bieger, A., Tissot, C., Lussier, F. Z., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.12.008 · Cited by 43
Liu, L., Zhang, C., Lv, X., Lai, X., Xu, L., Feng, J., Song, Y., Wang, S., & Zhan, S. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00731-1 · Cited by 42
Pang, K., Liu, C., Tong, J., Ouyang, W., Hu, S., & Tang, Y. (2022) · Nutrients · doi:10.3390/nu14194198 · Cited by 39
Effects of Plasma Lipids and Statins on Cognitive Function
Li, R., Wang, T., Lyu, P., Liu, Y., Chen, W., Fan, M., & Xu, J. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.225062 · Cited by 40
“The latest research showed that late-life measurements of HDL-C and triglycerides were not associated with increased risk of VaD, and HDL-C was not associated with the risk of MCI, AD, or any form of dementia.[24] A pooled analysis of two Finnish prospective population-based cohort studies (n = 13,275) found that the…”
BackgroundNovel therapeutic strategies for Alzheimer’s disease targeting brain cholesterol homeostasis
Samant, N. P., & Gupta, G. L. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14949 · Cited by 40
O’Hagan, R., Berg, A., Hong, C. G., Parel, P. M., Mehta, N. N., & Teague, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.972140 · Cited by 39
Zhang, X., Geng, T., Li, N., Wu, L., Wang, Y., Zheng, D., Guo, B., & Wang, B. (2022) · Nutrients · doi:10.3390/nu15010069 · Cited by 37
“There was a relationship between LDL-C level and the risk of VaD in one study [7], whereas many studies reported no significant associations with VaD risk [12].”
BackgroundResultFu, J., Liu, Q., Du, Y. J., Zhu, Y., Sun, C., Lin, H., Jin, M., Ma, F., Li, W., Liu, H., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.578742 · Cited by 39
“However, high cholesterol in later life was not associated with MCI, AD, dementia, or cognitive decline (Anstey et al., 2017).”
BackgroundLoera-Valencia, R., Ismail, M.-A.-M., Goikolea, J., Lodeiro, M., Mateos, L., Björkhem, I., Puerta, E., Romão, M. A., Gomes, C. M., Merino-Serrais, P., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02521-8 · Cited by 36
Bransby, L., Rosenich, E., Maruff, P. T., & Lim, Y. Y. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.119 · Cited by 40
Vascular Cognitive Impairment and Dementia
Sachdev, P. S., Bentvelzen, A. C., Gustafson, D., Hansra, G. K., Hosoki, S., Jiang, J., Lennon, M. J., Moro, M. Á., Saks, D., Samaras, K., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.008 · Cited by 54
Xu, C., Apostolova, L. G., Oblak, A. L., & Gao, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191023 · Cited by 35
“Furthermore, a recent meta-analysis on the association between serum cholesterol and dementia has identi-fiedsignificantgapsintheliteratureregardingHCandADrisk[16].”
Associations between vascular risk factors and subsequent Alzheimer’s disease in older adults
Lee, H., Kim, K., Lee, Y. C., Kim, S., Won, H., Yu, T. Y., Lee, E. M., Kang, J. M., Lewis, M., Kim, D. K., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00690-7 · Cited by 42
Zhang, Q., Zhang, M., Chen, Y., Cao, Y., & Dong, G. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215250 · Cited by 36
“A meta-analysis indicated that higher levels of cholesterol in midlife increase the risk of cognitive impairment in late life, but high cholesterol in late life was not associated with dementia or cognitive decline [22].”
Senff, J. R., Tack, R. W. P., Mallick, A., Gutiérrez-Martínez, L., Duskin, J. A., Kimball, T. N., Tan, B. Y., Chemali, Z. N., Newhouse, A. L., Kourkoulis, C. E., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-334925 · Cited by 43
Serum Cholesterol and Incident Alzheimer's Disease: Findings from the Adult Changes in Thought Study
Marcum, Z. A., Walker, R., Bobb, J. F., Sin, M., Gray, S. L., Bowen, J. D., McCormick, W., McCurry, S. M., Crane, P. K., & Larson, E. B. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15581 · Cited by 34
“Moreover, studies evaluating midlife cholesterol lacked clear information on age of cholesterol exposure.(4) To address some of these gaps, we evaluated extensive longitudinal clinical data from a prospective cohort with From the *Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washingto…”
BackgroundMethodInfluentialTrials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes
Kivipelto, M., Palmer, K., Hoang, T. D. M., & Yaffe, K. S. (2022) · Stroke · doi:10.1161/strokeaha.121.032614 · Cited by 41
Gul, R., Jan, H., Lalay, G., Andleeb, A., Usman, H., Zainab, R., Qamar, Z., Hano, C., & Abbasi, B. H. (2021) · Coatings · doi:10.3390/coatings11060717 · Cited by 33
Dagres, N., Chao, T., Fenelon, G., Aguinaga, L., Benhayon, D. A., Benjamin, E. J., Bunch, T. J., Chen, L. Y., Chen, S., Darrieux, F., et al. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2018.03.005 · Cited by 36
Cardiovascular risk and midlife cognitive decline in the Study of Women's Health Across the Nation
Derby, C. A., Hutchins, F., Greendale, G. A., Matthews, K. A., Sternfeld, B., Everson‐Rose, S. A., Kazlauskaite, R., Whitmer, R. A., & Brooks, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12300 · Cited by 37
Wang, Q., Zang, F., He, C., Zhang, Z., Xie, C., & Initiative, A. D. N. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-022-03786-w · Cited by 32
“Recently, a metaanalysis reported that high midlife total serum cholesterol significantly increases the risk of late-life AD, and may correlate with the onset of AD pathology [42].”
BackgroundSergi, D., Zauli, E., Tisato, V., Secchiero, P., Zauli, G., & Cervellati, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054403 · Cited by 34
Cholesterol and Dementia: A Long and Complicated Relationship
McFarlane, O., & Kędziora–Kornatowska, K. (2019) · Current Aging Science · doi:10.2174/1874609812666190917155400 · Cited by 36
Chung, H. S., Lee, J. S., Kim, J. A., Roh, E., Lee, Y. B., Hong, S. H., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, S. G., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00441 · Cited by 31
Prediction of Alzheimer’s disease with serum lipid levels in Asian individuals: a meta-analysis
Wu, Y., Wang, Z., Jia, X., Zhang, H., Zhang, H., Li, J., & Zhang, K. (2019) · Biomarkers · doi:10.1080/1354750x.2019.1571633 · Cited by 37
“…lipoprotein cholesterol (HDL-C, Reitz et al. 2010), low-density lipoprotein cholesterol (LDL-C, Matsuzaki et al. 2011), total cholesterol (TC, Anstey et al. 2017) and triglyceride (TG, Nagga et al. 2018) levels, the ratios of HDL-C or LDL-C and their interactions with other proteins (i.e.…”
BackgroundLai, A. Y., & McLaurin, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14130 · Cited by 34
High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia
Koch, M., DeKosky, S. T., Goodman, M., Sun, J., Furtado, J. D., Fitzpatrick, A. L., Mackey, R. H., Cai, T., Lopez, O. L., Kuller, L. H., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p119000473 · Cited by 29
Mancini, G., Dias, C., Lourenço, C. F., Laranjinha, J. A. N., Bem, A. F. D., & Ledo, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210122 · Cited by 34
“Cohort studies have reported that a high plasma cholesterol level, especially when measured at midlife, is associated with a poor cognitive outcome: cognitive decline, dementia, and AD [38].”
Xie, Y.-Y., Zhao, L., Gao, L., Xu, R., Gao, Y., Dou, K., Guo, Y., & He, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01729-4 · Cited by 28
“A meta-analysis synthesizing 34 cohort studies found no association between serum TC levels and mild cognitive impairment, Alzheimer’s disease (AD), vascular dementia, any dementia, or cognitive decline [3].”
MethodStatin use and safety concerns: an overview of the past, present, and the future
Mulchandani, R., Lyngdoh, T., & Kakkar, A. K. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1796966 · Cited by 34
Saleem, M., Herrmann, N., Dinoff, A., Mielke, M. M., OH, P. I., Shammi, P., Cao, X., Venkata, S. L. V., Haughey, N. J., & Lanctôt, K. L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161292 · Cited by 30
Fan, R., Zhao, L. Q., Ding, B., Xiao, R., & Ma, W. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1610606 · Cited by 27
Metadata
- Authors
- Anstey, K. J., Ashby-Mitchell, K., & Peters, R.
- Affiliations
- Australian National University (AU)
- Corresponding author
- Anstey, Kaarin J.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-11-29
- Volume
- 56
- Issue
- 1
- Pages
- 215-228
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5240556
- OpenAlex
- W2558803774
- Semantic Scholar
- 0c1251803f118cf5e382bfc6624ab0fbd3c53d8f
- Cited by
- 360
- References
- 61
- Citations by year
- 2026: 18 · 2025: 42 · 2024: 52 · 2023: 43 · 2022: 52 · 2021: 51 · 2020: 43 · 2019: 34 · 2018: 18 · 2017: 7
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- ANU Open Research (Australian National University) (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research (PDF-2012-05-197)
- National Health and Medical Research Council (1002560)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- serum cholesterol
- MeSH terms
- Alzheimer Disease, Cholesterol, Dementia, Humans, Risk Factors, Cohort Studies, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
